Citius Pharma Q3 2024 GAAP EPS $(0.06) Misses $(0.05) Estimate
Portfolio Pulse from Benzinga Newsdesk
Citius Pharma (NASDAQ:CTXR) reported a Q3 2024 GAAP EPS of $(0.06), missing the analyst consensus estimate of $(0.05) by 20%. This result is unchanged from the same period last year.
August 12, 2024 | 9:41 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citius Pharma reported a Q3 2024 GAAP EPS of $(0.06), missing the analyst consensus estimate of $(0.05) by 20%. This result is unchanged from the same period last year.
The earnings miss by 20% is likely to negatively impact the stock price in the short term. The fact that the EPS is unchanged from last year suggests no improvement in financial performance, which could further weigh on investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100